Schaeffer Orlov S Nicole 4
4 · INSMED Inc · Filed Nov 14, 2025
Insider Transaction Report
Form 4
INSMED IncINSM
Schaeffer Orlov S Nicole
Chief People Strategy Officer
Transactions
- Sale
Common Stock
2025-11-12$192.45/sh−4,078$784,811→ 62,383 total - Sale
Common Stock
2025-11-12$193.64/sh−6,575$1,273,183→ 55,808 total - Sale
Common Stock
2025-11-12$194.44/sh−19,183$3,729,943→ 36,625 total - Exercise/Conversion
Stock Option (right to buy)
2025-11-12−30,000→ 15,760 totalExercise: $26.46Exp: 2031-05-12→ Common Stock (30,000 underlying) - Sale
Common Stock
2025-11-12$195.88/sh−164$32,124→ 36,461 total - Exercise/Conversion
Common Stock
2025-11-12$26.46/sh+30,000$793,800→ 66,461 total
Footnotes (5)
- [F1]This is the weighted average sales price representing 4,078 shares sold at prices ranging from $192.00 to $192.95 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
- [F2]This is the weighted average sales price representing 6,575 shares sold at prices ranging from $193.02 to $194.01 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
- [F3]This is the weighted average sales price representing 19,183 shares sold at prices ranging from $194.02 to $194.95 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
- [F4]This is the weighted average sales price representing 164 shares sold at prices ranging from $195.42 to $195.96 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
- [F5]The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable.